TLX
Telix Pharmaceuticals LimitedNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.31B
P/E Ratio
—
EPS
$-0.02
Beta
0.61
52W High
$20.00
52W Low
$6.28
50-Day MA
$7.73
200-Day MA
$10.12
Dividend Yield
—
Profit Margin
-0.89%
Forward P/E
1250.00
PEG Ratio
—
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company is headquartered in North Melbourne, Australia.
Fundamentals
| Revenue (TTM) | $803.79M |
| Gross Profit (TTM) | $381.85M |
| EBITDA | $32.46M |
| Operating Margin | 1.94% |
| Return on Equity | -1.86% |
| Return on Assets | 1.15% |
| Revenue/Share (TTM) | $2.38 |
| Book Value | $1.23 |
| Price-to-Book | 7.44 |
| Price-to-Sales (TTM) | 4.12 |
| EV/Revenue | 4.182 |
| EV/EBITDA | 95.62 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 49.30% |
| Shares Outstanding | $338.78M |
| Float | $272.59M |
| % Insiders | 0.00% |
| % Institutions | 0.34% |
Historical Volatility
HV 10-Day
52.20%
HV 20-Day
47.62%
HV 30-Day
55.34%
HV 60-Day
68.01%
HV Rank
47.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($21.47 target)
5
BuyData last updated: 4/9/2026